"Dr. Vallera and colleagues enrolled 25 chemo-refractory patients with previously treated pre-B acute lymphoblastic leukemia, chronic lymphocytic leukemia, or non-Hodgkin lymphoma whose tumors expressed CD19 and/or CD22. Eight patients had previously undergone unsuccessful bone marrow transplantations. Patients had a median of three prior therapies and their median age was 55 years.
:
Two of the 10 patients who could be evaluated had durable objective responses, with one complete remission after two cycles of therapy.
:
All patients received a single cycle of the immunotoxin therapy at varying doses between 40 and 80 µg/kg administered as four intravenous infusions for 2 hours every other day.
The most common adverse events were low albumin, weight gain, transaminitis, and fever. These events were transient and were generally grade 1 or 2 in the patients treated at higher doses (≥ 40 µg/kg per day).
Two patients had a dose-limiting toxicity with the 40- and 60-µg/kg doses.
The patient who achieved complete remission had relapsed CD19-positive, CD22-positive diffuse large B-cell lymphoma and was treated with the 60-µg/kg dose."
These were tough to treat patients.
cancernetwork.com/news/immu...
Neil
Photo: We've had some very strong winds this past year, bringing down many trees, which in turn can bring down farm fences. This tree amazingly dropped on a dropper (the steel fence post) and embedded itself sufficiently to stay stuck there when the tree was sawn up.